Roivant Sciences Ltd.: Initiation Of Coverage – Acquisition Of New Programs To Diversify In Biosciences!

This is our first report on Roivant. The company’s Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous growth of VTAMA, ROIV’s best-selling branded topical in psoriasis, recording over 300,000 prescriptions and revenues of $20.7 million. Additionally, the pipeline for Roivant has compelling developments, with brepocitinib showing promising potential in orphan rheumatology. The company also has a cash balance of $6.7 billion, which provides the necessary capital for future programs and opportunities.